Loss of mineralocorticoid receptor signaling selectively in cardiomyocytes can ameliorate cardiac fibrotic and inflammatory responses caused by excess mineralocorticoids. The aim of this study was to characterize the role of cardiomyocyte mineralocorticoid receptor signaling in ischemia-reperfusion injury and recovery and to identify a role of mineralocorticoid receptor modulation of cardiac function. Wild-type and cardiomyocyte mineralocorticoid receptor knockout mice (8 weeks) were uninephrectomized and maintained on (1) high salt (0.9% NaCl, 0.4% KCl) or (2) high salt plus deoxycorticosterone pellet (0.3 mg/d, 0.9% NaCl, 0.4% KCl). After 8 weeks of treatment, hearts were isolated and subjected to 20 minutes of global ischemia plus 45 minutes of reperfusion. Mineralocorticoid excess increased peak contracture during ischemia regardless of genotype. Recovery of left ventricular developed pressure and rates of contraction and relaxation post ischemia-reperfusion were greater in knockout versus wild-type hearts. The incidence of arrhythmic activity during early reperfusion was significantly higher in wild-type than in knockout hearts. Levels of autophosphorylated Ca 2+ /calmodulin protein kinase II (Thr287) were elevated in hearts from wild-type versus knockout mice and associated with increased sodium hydrogen exchanger-1 expression. These findings demonstrate that cardiomyocyte-specific mineralocorticoid receptor-dependent signaling contributes to electromechanical vulnerability in acute ischemia-reperfusion via a mechanism involving Ca 2+ /calmodulin protein kinase II activation in association with upstream alteration in expression regulation of the sodium hydrogen exchanger-1. (Hypertension. 2015;66:970-977.
M ineralocorticoid receptor (MR) antagonists are beneficial in heart failure and can reduce the incidence of sudden cardiac death, although side effects (including hyperkalemia) limit their widespread use. [1] [2] [3] Establishing tissue-specific roles for MR signaling is critical to develop selective target therapies to achieve the beneficial effects of MR blockade without deleterious side effects.
MR signaling involvement in systemic fluid homeostasis is well established. Emerging evidence identifies an important role of MR in pathophysiologic regulation of cardiac function. Clinical and experimental studies demonstrate that mineralocorticoid excess is associated with cardiac inflammation, oxidative stress, fibrosis, and hypertrophyresponses characterized by cardiomyocyte gene expression shifts. In vitro and ex vivo studies provide evidence for MR modulation of cardiomyocyte electromechanical function, although a clear mechanistic understanding has not yet been resolved. Aldosterone has been found to increase contractility in isolated hearts and shortening in cardiomyocytes (via a mechanism involving intracellular pH modulation). 4, 5 Consistent with this positive inotropic effect, evidence for aldosterone-mediated augmentation of cardiomyocyte calcium (Ca 2+ ) current density has been observed. [6] [7] [8] In contrast, other cardiomyocyte studies have demonstrated no change in either Ca 2+ signaling or contractility with sodium-hydrogen exchanger-1 (NHE-1) activation. 9 Cardiomyocyte-specific MR overexpression is linked with cardiac arrhythmia in the absence of fibrotic or inflammatory responses, suggesting direct cardiomyocyte involvement in MR-mediated arrhythmogenesis. 10 Collectively these data show MR capacity to regulate cardiomyocyte operation via multiple mechanisms, but an understanding of how these responses contribute to functional outcomes in different settings is not clear.
MR participation in promoting myocardial injury responses to ischemia has been described. After myocardial infarction, cell selective MR knockout in cardiomyocytes attenuates the extent of adverse left ventricular functional deterioration, hypertrophy, fibrosis, and angiogenesis with improved extracellular matrix structural organization. 11 Other studies of infarcted hearts have provided evidence for the involvement of Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) in mediating aldosterone/MR-induced cardiac dysfunction. 12 The direct involvement of cardiomyocyte-specific MR in this CaMKII action has not yet been determined.
We have previously shown that selective cardiomyocyte MR null mice are protected from deoxycorticosterone/salt (DOC/salt)-mediated cardiac fibrosis and inflammation. 13 The aim of this study was to assess the role of the cardiac MR in mediating acute cardiac responses to ischemia and reperfusion challenge in normal and high levels of chronic systemic exposure to mineralocorticoids. Functional and molecular signaling responses of hearts from cardiomyocyte MR null mice were examined. We have identified a significant contribution of cardiomyocyte MR in perpetrating ischemiareperfusion-related arrhythmogenesis and electromechanical dysfunction.
Methods
Methods are available in the online-only Data Supplement.
Results

Cardiomyocyte MR Knockout and Cardiac Structure
Knockout (KO) mice exhibited somatic phenotypes comparable with wild-type (WT) mice as previously described. 13 Body weight, tibia length, and heart weight ratio were not different in WT and KO vehicle or DOC/salt treatment groups, consistent with our previous studies (Table 1) . 13 
Cardiac MR and Estrogen Receptor Gene Expression
Myocardial MR mRNA levels were significantly lower in KO than in WT hearts, confirming knockdown of MR in cardiomyocytes ( Figure S1A in the online-only Data Supplement). 13 Residual levels of MR mRNA expression in KO hearts reflect MR expression in noncardiomyocyte cell types in the myocardium. Signaling crosstalk between the MR and estrogen receptor has been recently reported. 14 Cardiac mRNA levels for estrogen receptor-α, estrogen receptor-β, and G proteincoupled estrogen receptor were similar in all treatment groups ( Figure S2 ), indicating that neither loss of MR signaling nor enhanced MR signaling alters cardiac expression of these other nuclear receptors.
Mineralocorticoid Excess Induces Cardiac Fibrosis and Inflammation
DOC/salt treatment increased cardiac collagen content in WT hearts only, consistent with our previous findings ( Figure S1B ). 13 Macrophage infiltration was equivalent in vehicle-treated WT and KO hearts, consistent with previous studies. 13 DOC/salt increased macrophage infiltration in WT but not in KO hearts, demonstrating a role of cardiomyocyte MR signaling in cardiac macrophage recruitment ( Figure S1C ).
MR Versus Mineralocorticoid-Mediated Basal and Ischemia Functional Responses
Baseline (normoxic) ex vivo cardiac contractile function did not differ between WT and KO hearts in vehicle-treated hearts ( Table 2 ). Chronic DOC/salt treatment did not regulate basal cardiac contractile function (Table 2) . Thus, basal function was preserved in the hearts of mice treated with chronic DOC/ salt and with loss of cardiomyocyte MR.
Time to ischemic contracture, indicated by end-diastolic pressure reaching 15 mm Hg during ischemia, was equivalent for WT and KO hearts treated with vehicle; DOC/salt treatment reduced time to contracture in both genotypes ( Figure 1A ). Peak contracture was equivalent for WT and KO hearts given vehicle. Chronic DOC/salt treatment increased indicators of ischemic response regardless of the presence of MR in cardiomyocytes, suggesting MR activation in noncardiomyocyte cell types may underlie these effects ( Figure 1B and 1C).
Comparison of basal and ischemic functional parameters between vehicle-treated and untreated hearts (mice not subjected to uninephrectomy or high salt diet) demonstrated that vehicle treatment did not modulate cardiac function in WT and KO hearts (Table S3 ).
Loss of Cardiomyocyte MR Improves Cardiac Function After an Acute Ischemic Event
Post ischemia, reperfusion recovery of left ventricular developed pressure and rates of cardiac contraction and relaxation were significantly higher in KO hearts than in WT hearts under both normal (vehicle and untreated) and high mineralocorticoid levels (Figure 2A-2C; Table S3 ). End-diastolic pressure and coronary flow were not different between WT and KO hearts at the end of reperfusion (data not shown). These findings provide evidence for postischemic cardiac functional recovery mediated by cardiomyocyte MR, but independent of exogenous mineralocorticoid.
Ectopic Beats Are Reduced by Loss of Cardiomyocyte MR
Early reperfusion arrhythmias can be triggered by the Ca 2+ and sodium (Na + ) accumulation that occurs during ischemia, associated with destabilization of the intracellular sarcoplasmic reticulum Ca 2+ store. KO hearts had reduced ectopic beats during early reperfusion compared with WT hearts under normal mineralocorticoid levels. DOC/salt-treated KO hearts also displayed fewer ectopic beats than DOC/salt-treated WT hearts ( Figure 3 ; Figure  S3 ). Arrhythmic activity was not apparent under basal conditions in WT and KO hearts, suggesting that MR modification does not affect baseline cardiac rhythm. An arrhythmogenic role of MR was revealed in stress conditions. These data indicate cardiac arrhythmia during early reperfusion is dependent on cardiomyocyte MR activation but not on mineralocorticoid levels.
MR-Dependent Cardiomyocyte Na and Ca Handling
Contractile recovery post ischemia depends on homeostatic regulation of Ca 2+ , Na + , and proton (H + ) levels via modulation of action of key ionic transporters. Autophosphorylated CaMKII (P-CaMKII (Thr287)) was higher in WT hearts than in KO hearts, regardless of treatment ( Figure 4A ); there was no difference in levels of oxidized CaMKII (ox-CaMKII(Met281/2)) between WT and KO hearts ( Figure  S4A ). Protein levels of NHE-1 were also greater in WT than in KO hearts, regardless of mineralocorticoid status ( Figure 4B ). DOC/salt treatment did not affect expression levels of sarcoplasmic reticulum Ca 2+ ATPase 2a (SERCA2a), sarcoplasmic reticulum Ca 2+ release channel (RyR2), or phosphorylation status of phospholamban (P-PLB(Thr17)) in WT or KO hearts ( Figure S4B -S4D). These data demonstrate cardiac functional responses to ischemia-reperfusion in KO and WT are differentially modulated by a mechanism Cell death markers involved in autophagy and apoptosis induction were also assessed and were not different in WT and KO groups, control or DOC/salt treated ( Figure S5A-S5E ).
Female and Male Cardioprotective Effects of MR Deletion Are Similar
To examine sex-specificity of KO responses, parallel experiments were performed in age-matched female mice. Gene expression analysis confirmed that group differences in MR expression levels in females were similar to those observed in males ( Figure S6 ). Cardiac weight indices were similar for female vehicle-treated WT and KO hearts. DOC/salt treatment increased cardiac weight in WT compared with KO mice (Table S4 ). Cardiac fibrotic, inflammatory, and reperfusion functional responses were equivalent in male and female hearts (Figures S7 and S8; Table S5 ). Some differences in the time course and amplitude of contracture development in ischemia were observed between females and males ( Figure S9 ), which may reflect a hypertrophic response to excess mineralocorticoid treatment which is present in females but not in males (Table S4 ).
Discussion
This study provides novel demonstration that cardiomyocyte MR signaling is instrumental in determining cardiac functional recovery after acute ischemia-reperfusion insult. Although deletion of cardiomyocyte MR had no effect on basal cardiac function, during reperfusion KO hearts exhibited enhanced recovery of cardiac systolic function and reduced arrhythmia. Excess mineralocorticoid treatment did not regulate basal ex vivo cardiac function or recovery post ischemia in the presence or absence of cardiomyocyte MR. Molecular analysis revealed increased P-CaMKII activation (Thr287) and NHE-1 expression in KO hearts. These findings demonstrate for the first time that cardiomyocyte-specific MR-dependent signaling contributes to electromechanical vulnerability in acute ischemia-reperfusion via a mechanism involving CaMKII activation in association with upstream alteration in expression regulation of NHE-1. Our data add new insight into the role of cardiomyocyte MR signaling in ischemic cardiac injury.
Functional Recovery Was Improved by MR Deletion in Cardiomyocytes
Recovery of left ventricular developed pressure and rates of cardiac contraction and relaxation were greater in KO than in WT hearts at the end of reperfusion. MR antagonists benefit functional improvement after myocardial infarction. 15, 16 This is the first investigation to demonstrate Interestingly, chronic in vivo exposure to mineralocorticoid excess did not modify end reperfusion cardiac function in either WT or KO hearts, suggesting that in this injury context the MR involvement is independent of mineralocorticoid ligand action. Our data show that the functional benefits of loss of cardiomyocyte-specific MR signaling can be achieved early post ischemic insult and are essentially equivalent for males and females.
Cardiomyocyte MR Mediates Arrhythmogenesis
Suppressed occurrence of ectopic activity during early reperfusion in KO revealed that cardiomyocyte MR plays a role in facilitating dysrhythmia. This finding is consistent with the reduced sudden cardiac death incidence observed clinically with MR antagonist treatment. The enhanced systolic function and decreased arrhythmia in the KO were associated with a reduction in P-CaMKII(Thr287) and no change in ox-CaMKII(Met281/2) levels. Ox-CaMKII(Met281/2) has previously been shown to be involved in pathophysiological MR signaling in a setting of chronic ischemic heart disease. Taken together, these findings indicate that although ox-CaMKII(Met281/2) plays a role in long-term remodeling induced by mineralocorticoid excess, a P-CaMKII(Thr287) effect is more prominent in the acute setting. 12 Further work is required to prove definitively the causational involvement of different CaMKII post-translational modifications in acute and chronic ischemia.
In this study, we have shown that MR deletion produces a decrease in expression of the NHE-1. This is consistent with other experimental studies showing inhibition of NHE-1 suppresses ventricular arrhythmia. 17 During ischemia-reperfusion augmented Na + influx driven by intracellular proton accumulation via Na + -H + exchange, couples to consequential increase in Ca 2+ influx through Na + -Ca 2+ exchange, with resultant sarcoplasmic reticulum loading instability instigating arrhythmia and systolic dysfunction. 18 The suppression of arrhythmia and systolic functional enhancement seen in the KO hearts thus identifies the cardiomyocyte MR as a key mediator of these downstream deleterious outcomes through joint NHE-1 and CaMKII regulatory mechanisms ( Figure 5 ).
There is also evidence that CaMKII can activate the NHE-1 through direct phosphorylation, constituting a positive feedback arrhythmogenic relationship between these 2 effector proteins, consistent with the present finding of reduced P-CaMKII(Thr287) in the KO. 19, 20 No differences in the expression levels of SERCA2a or RyR2 were observed nor in the activation of the SERCA2a regulator P-PLB (Thr17). This suggests an MR-mediated action of P-CaMKII(Thr287), which does not involve modulation of levels of these sarcoplasmic reticulum uptake and release proteins.
Basal Cardiac Function Maintained With MR-Mediated Fibrosis
Basal cardiac function was not different between WT and KO. This observation that loss of cardiomyocyte MR does not modulate resting cardiac function is consistent with previous cardiomyocyte MR knockout studies conducted on C57Bl6 mice using the myosin light chain 2v and atrial myosin light chain promoter to drive Cre recombinase expression. 11, 13, 21 Thus, difference in postischemic functional outcomes cannot be attributed to difference in preischemic status per se.
Cardiomyocyte MR is involved in the development of cardiac fibrosis and macrophage infiltration. 13 Previous studies, using the same MLC2v cardiomyocyte MR KO mouse strain as the current study, have confirmed MR deletion on cardiomyocytes which resulted in increased expression of chemoattractant proteins and cytokines with upregulation of the connective tissue growth factor-transforming growth factor β-collagen type III profibrotic pathway. 13 An increase in fibrosis was observed in WT hearts treated with DOC/salt, but not in KO hearts. This confirms our earlier finding establishing cardiomyocyte MR involvement in the development and progression of cardiac fibrosis. 13 Other cardiomyocyte MR knockout studies have shown either no reduction in fibrosis or reduced fibrosis with improved collagen structural organization in KO hearts, depending on the specific disease model and the origin of genetic model. 11, 21 These various observations imply that the antifibrotic benefit of MR blockade depends on the nature and severity of disease setting. In this study, MR ablation prevented fibrosis development, but given the finding that basal performance across all groups was similar, it can be concluded that the modest extent of fibrosis development after 8-week DOC/salt treatment did not affect functional status.
Developmental changes in gene expression, capable of modifying development and regulation of cardiac function in KO hearts, are unlikely as the adult myosin Cre (MLC2v) used to generate KO mice is expressed from neonatal day 7 to 10. Importantly, no difference in either basal cardiac function or arrhythmia before ischemia was observed in WT and KO hearts, and our findings are consistent with those observed with acute MR antagonism. 22 MR expression was significantly reduced in KO hearts compared with WT hearts; although variability in these data may arise from small shifts in MR expression in nonmyocyte cell types, it has previously been demonstrated that MR expression does not respond to DOC treatment. 23 Another important consideration is blood pressure responses in WT and KO mice to excess mineralocorticoid treatment. Previously, we have shown that both WT and KO mice become mildly hypertensive after 8-week DOC/salt treatment. 13 Importantly, vehicle-treated hearts had equivalent recovery of cardiac function post ischemia compared with untreated hearts, indicating that there is no blood pressuredependent effect on functional outcomes following uninephrectomy and high-salt diet.
Ischemic Functional Response Is Influenced by DOC/Salt, Not Deletion of Cardiomyocyte MR
Loss of cardiomyocyte MR did not modify ischemic functional parameters. In contrast, DOC/salt treatment reduced the time to contracture and increased peak contracture in WT and KO hearts compared with vehicle treatment. These findings provide evidence that ischemic functional responses are a consequence of ligand activation of MR in noncardiomyocyte cell types (ie, vascular smooth muscle or endothelial cells) and not a direct action of cardiomyocyte MR signaling, although further experiments are required to confirm these actions.
It has been previously established that MR antagonists reduce infarct size and apoptosis in ex vivo rodent hearts. 24 In the model of global no flow ischemia used in this study, no difference was observed in levels of proteins involved in apoptosis or autophagy induction between WT and KO hearts from animals of both normal and excess mineralocorticoid in vivo exposure levels, a finding consistent with previous cardiomyocyte MR knockout studies. 21 These data indicate that cardiomyocyte MR may not play a role in induction of programmed cell death pathway signaling in the early reperfusion window.
Cardiac MR Is Not Ligand-Selective
MR ligand selectivity is regulated in a tissue-specific manner by the activity of 11β-hydroxysteroid dehydrogenase type 2,which converts glucocorticoids to inactive metabolites, resulting in MR being responsive to only mineralocorticoids. 25, 26 Cardiomyocyte MR do not discriminate between glucocorticoid and mineralocorticoid ligands because of the absence of 11β-hydroxysteroid dehydrogenase type 2. 27, 28 Moreover, evidence suggests that MR-glucocorticoid complexes or unliganded receptors can be activated under stress conditions, such as ischemia-reperfusion. 29, 30 In this study, the finding that basal cardiac function was not modulated by cardiomyocyte MR deletion or DOC/salt treatment indicates that in a nonischemic state MR do not have a significant role in the regulation of myocardial function. Ischemic contracture responses were increased by excess mineralocorticoids, providing evidence to support a role of mineralocorticoids acting in nonmyocyte cell types to increase ischemic functional responses, for example, vascular smooth muscle cells. 31 Recovery during reperfusion was greater in KO hearts even under normal mineralocorticoid levels, demonstrating that cardiomyocyte MR can mediate functional responses independent of mineralocorticoid ligand activation. These findings are consistent with glucocorticoid activation of MR specifically in conditions of ischemia-reperfusion. Further work is required to understand the nuanced roles of different ligands in cardiomyocyte MR activation in different pathophysiologic conditions and in the complex neurohormonal interactions involved in medicating cardiac damage in situ during myocardial infarction.
Perspectives
MR antagonists are known to have clear benefit clinically, in relation to cardiac structural remodeling and in sudden cardiac death prevention. The cellular mechanisms of MR signaling in different cardiovascular cell types are not well delineated. Our data show for the first time that selective MR deletion from cardiomyocytes suppresses arrhythmia and improves cardiac functional recovery via a Na + /Ca 2+ modulatory mechanism. Furthermore, the protective effect of MR deletion on ischemic recovery is achieved with maintenance of normal basal cardiac performance, and in the context of a moderate level of mineralocorticoid stimulated cardiac fibrosis. These findings highlight the important role of cardiomyocyte MR in mediating functional pathology in the acute phase of postischemia reperfusion. The MR plays an important role in several different cell types that may also be involved in the cardiac responses to ischemia. Our data also suggest that MR-dependent responses in nonmyocyte cell types, such as vascular smooth muscle cells, can modify the cardiac injury response during acute ischemia. The cardiomyocyte MR is, however, an attractive target for selective MR blockade for both sexes to achieve cardiac protection with the advantage of avoiding systemic side effects. What Is New?
Sources of Funding
• We show that cardiomyocyte-specific mineralocorticoid receptor (MR) signaling is critical in determining acute functional recovery after ischemia-reperfusion injury in both males and females.
• Ablation of cardiomyocyte MR was associated with improved recovery of left ventricular developed pressure during reperfusion, improved cardiac rhythm, and lower P-CaMKII(Thr287) activation and sodium-hydrogen exchanger-1 expression
What Is Relevant?
• Selective loss of cardiomyocyte MR signaling has clear cardioprotective outcomes and supports the development of cardiac-specific therapies for heart failure and post myocardial infarction that avoid negative side effects of current MR antagonists.
Supplementary methods
Experimental animal model
All procedures involving animals were approved by the relevant Institute Animal Ethics and Biosafety Committees. Male MR flox/flox (wild type, WT) and cardiac-specific MR-null MR flox/flox /MLC2v Cre+mice (KO) (20-30g) were uninephrectomised and given vehicle or DOC (7 mg s.c. pellet/3wk) and maintained on standard chow plus 0.9 % NaCl plus 0.4 % KCl drinking solution to accelerate progression of excess mineralocorticoid influence on cardiovascular phenotype over the 8 week treatment period. Selected parallel experiments were performed in age-matched untreated (no surgery plus water to drink) and female mice as indicated.
Assessment of cardiac function ex vivo
WT and KO mice were anesthetised with sodium pentobarbitone (70mg/kg, i.p). A thoracotomy was performed, hearts excised into ice-cold perfusion fluid and the aorta cannulated. Hearts were retrogradely perfused with oxygenated (95% O 2 -5% CO 2 ) modified Krebs-Henselit buffer (37.0°C, pH 7.4) in Langendorff mode at a constant pressure of 80mmHg and instrumented for pressure recording as previously described (ADInstruments, Labchart v7.2). 1 The modified Krebs-Henselit buffer contained (in mmloes per liter): 119.0 NaCl, 11.0 glucose, 22.0 NaHCO 3 , 4.7 KCL, 1.2 MgCl, 1.2 KH 2 PO 4 , 0.5 EDTA, 1.75 CaCl, 2.0 Na pyruvate. Hearts were perfused for 30 minutes prior to 20 minutes of global no flow ischemia and 45 minutes of reperfusion. Pacing at 420 beats per minute was maintained during the stabilisation period and recommenced at 2 minutes reperfusion. Arrhythmia incidence was assessed from left ventricle pressure records as previously validated from electrocardiogram measurements. 2 Hearts were removed from the apparatus and a mid-section cut and fixed in formalin overnight for histological analysis, the remainder was snap frozen for protein and mRNA analysis.
Histological and immunohistochemical analyses
Assessment of immunostaining was carried out in a blinded manner. Approximately 20 fields were sampled per tissue for determination of percent collagen area. Paraffin-embedded, 5 μm thick heart sections were incubated for 1 hour with MAC2 (1:200; eBioscience, CA), followed by the appropriate biotinylated secondary antibody for 45 minutes at room temperature and then incubated with ABC complex (Vectastain, Vector Laboratories, CA) for 45 min. Positive staining was visualized by incubation with 3,3-diaminodenzidine (DAKO Corp., CA), and the tissues were counterstained with hemotoxylin. An optical dissector approach was used to quantify infiltration of macrophages using the Computer-Assisted Stereological Toolbox (C.A.S.T.-GRID) software package, version 1.10 (Olympus DK A/s, Denmark). Histological analysis for collagen was performed on tissues stained with 0.1% Sirius Red (Sigma-Aldrich, Australia) as previously described. 3 Tissue sections were sampled using an unbiased systematic approach where the investigator was blinded to the identity of the sections.
Protein analysis and immunoblotting
Tissues were homogenized with a Polytron tissue grinder in the following solution (mM): 20 Tris-HCL pH6.8, 5 EGTA, 5 NaF, 0.5 Na3VO4 + protease inhibitor cocktail (Complete, Roche) (4C, 5-7.5% w/v) and reconstituted in 2X sodium dodecyl sulfate sample buffer. Concentration of the total protein fraction was determined by modified Lowry assay. Polyacrylmamide gels (12%) were loaded with equal amount of sample protein (3-21ug) for SDS-PAGE/Western blot analysis. Western blot experiments were performed using equal protein loading, achieved by performing multiple Lowry assay to confirm protein concentration within ±5%, quantified by coomassie staining to confirm equal loading. A calibrator sample was run across all membranes to normalize samples for differences in chemiluminescent signal development. Chemiluminescent imaging and analysis completed in a blinded manner (Image Lab V4.0 software, Bio-Rad, CA). Primary antibodies utilized listed in Table S1 . Secondary antibody utilized: anti-rabbit (1:2000) HRPconjugated (GE Healthcare UK Ltd, UK).
Quantitative PCR
Total mouse heart RNA was prepared with Ultraspec (Fisher Scientific). For each sample, 500 ng of total RNA was reversed transcribed using random hexamer primers and SuperScript III reverse transcription (Invitrogen) in a total volume of 20 μl. Quantitative PCR amplification was performed on Applied Biosystems 7900HT Real-Time PCR instrument using SYBR Green reaction mix Applied Biosystems). Data was analyzed with SDS Automation Controller software (version 2.3; Applied Biosystems, Life Technologies) and normalized to glyceraldehyde 3-phosphate dehydrogenase mRNA levels. Polymerase chain reaction (PCR) was carried out using primer sets listed in Table S2 . PCR targets: MR, estrogen receptor alpha (ERα), estrogen receptor beta (ERβ) and g-protein coupled estrogen receptor (GPER).
Statistical analysis
All data sets were analysed by Two Way ANOVA and Bonferroni's post hoc test (GraphPad Prism version 5.0a, GraphPad Software, CA). Differences between mean values were considered significant at P<0.05. All  Table S1 . A Antibodies us sed for weste ern blot. 
